Evan Y Yu

23PUBLICATIONS
262CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

|Mar 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.

Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci

|Mar 04, 2026
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Evan Y Yu, Vivek Narayan, Giuseppe Esposito

|Feb 26, 2026
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Feb 24, 2026
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs.

Evan Y Yu, Christian Gratzke, Mauricio Burotto

|Nov 02, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis.

Evan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka

Pageof 4

Frequent Collaborators

6 joint publications

Heather H Cheng

5 joint publications

Peter S Nelson

5 joint publications

Roman Gulati

4 joint publications

Michael T Schweizer